• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Pfizer (NY:PFE)

    27.98 +0.21 (+0.77%)
    Streaming Delayed Price Updated: 3:25 PM EDT, Mar 31, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Pfizer

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    99 100 Next >
    Which S&P500 stocks are the most active on Tuesday? ↗
    Via Chartmill
    News headline image
    Biotech Defies Gravity: Sarepta and Corcept Lead Midday Healthcare Rally Amidst Market Volatility
    In a trading session characterized by sharp declines across the technology and industrial sectors, the healthcare industry emerged as a resilient fortress on March 31, 2026. While the broader S&P 500... 
    Via MarketMinute
    Topics Economy Intellectual Property Stocks
    News headline image
    Moderna 2.0: The mRNA Pioneer’s Pivot to Oncology and the Path to 2028 Profitability
    As of March 31, 2026, Moderna Inc. (NASDAQ: MRNA) finds itself at a defining historical junction. After years of being defined by a single, world-altering product—its COVID-19 vaccine—the... 
    Via Finterra
    Topics Initial Public Offering
    Pfizer Inc. (NYSE:PFE) Shows Strong Technical Setup for Potential Breakout ↗
    Via Chartmill
    News headline image
    Prediction: Buying Pfizer Stock Today Could Set You Up for Life ↗
    Pfizer is behind Eli Lilly and Novo Nordisk in the GLP-1 race, but long-term investors shouldn't count the company out. 
    Via The Motley Fool
    Topics Intellectual Property
    News headline image
    1 Reason This Biotech Stock Could Triple Before Year-End ↗
    This little-known biotech could have a big hit on its hands with VK2735, a GLP-1 weight loss drug candidate. 
    Via The Motley Fool
    News headline image
    Is Now the Time to Buy Salesforce? Here's What the Numbers Reveal ↗
    Salesforce's numbers seem to add up to the stock being a solid pick. 
    Via The Motley Fool
    Topics Artificial Intelligence
    News headline image
    Could Buying Eli Lilly Today Set You Up for Life? ↗
    Eli Lilly is leading the GLP-1 market, and investors are enthralled with the stock. 
    Via The Motley Fool
    Topics Intellectual Property
    News headline image
    Sarepta Therapeutics (SRPT) Stock Surges 34.98% on Breakthrough Clinical Data
    CAMBRIDGE, MA — March 26, 2026 — Shares of Sarepta Therapeutics (NASDAQ:SRPT) skyrocketed 34.98% in heavy trading today, marking the biotech giant's most explosive single-day gain in over two years.... 
    Via MarketMinute
    News headline image
    Is Pfizer Stock a Buy After This Win? ↗
    Good news has been scarce for this beaten-down drugmaker. 
    Via The Motley Fool
    News headline image
    The $6.7 Billion Pivot: A Deep Dive into Terns Pharmaceuticals (TERN) and the Merck Acquisition
    On this Wednesday, March 25, 2026, the biotechnology sector has been electrified by the announcement that Merck & Co. (NYSE: MRK) will acquire Terns Pharmaceuticals, Inc. (NASDAQ: TERN) in an all-cash... 
    Via Finterra
    Topics Initial Public Offering Intellectual Property World Trade
    News headline image
    Sarepta Therapeutics (SRPT) at a Crossroads: A 2026 Deep Dive into the Future of Genetic Medicine
    As of March 25, 2026, Sarepta Therapeutics (NASDAQ: SRPT) stands at a pivotal, albeit bruising, crossroads in the history of genetic medicine. Once the darling of the biotechnology sector for its... 
    Via Finterra
    Topics Economy Intellectual Property Retirement
    News headline image
    Merck & Co. (MRK) 2026 Analysis: Navigating the Keytruda Cliff with Pipeline-Driven Resilience
    As of March 25, 2026, Merck & Co., Inc. (NYSE: MRK) stands at a pivotal crossroads in its 135-year history. Known globally as a titan of oncology and vaccines, the Rahway, New Jersey-based... 
    Via Finterra
    Topics Artificial Intelligence Economy Intellectual Property
    Stay informed about the most active stocks in the S&P500 index on Tuesday's session. ↗
    Via Chartmill
    News headline image
    Pfizer Invites Public to View and Listen to Webcast of May 5 Conference Call with Analysts
    From Pfizer Inc.
    Via Business Wire
    News headline image
    Pfizer To Rally More Than 34%? Here Are 10 Top Analyst Forecasts For Tuesday ↗
    Analysts change ratings & price targets for HSCS, ONDS, STRO, PFE, HST, CABA, INSM, PVH. See full list & how others rate each stock. 
    Via Benzinga
    News headline image
    Bristol-Myers Squibb Shares Jump 3.3% on Robust 2026 Guidance and High Dividend Yield
    Shares of pharmaceutical giant Bristol-Myers Squibb (NYSE:BMY) climbed 3.3% in early trading on Monday, March 23, 2026, after the company issued a surprisingly robust financial outlook for the fiscal... 
    Via MarketMinute
    Topics Economy Initial Public Offering Intellectual Property
    News headline image
    Pfizer Stock Is Doing Something It Hasn't Done Since 2022 ↗
    Up until recently, the stock has been a chronic underperformer. 
    Via The Motley Fool
    Topics Economy Intellectual Property
    News headline image
    5 High-Yield Stocks to Shield Your Portfolio From the Storm ↗
    Via MarketBeat
    News headline image
    Valneva-Pfizer Lyme Shot Stumbles Yet Keeps Regulatory Path Alive ↗
    Valneva stock drops after Phase 3 Lyme vaccine misses primary endpoint; secondary data shows efficacy as Pfizer backs regulatory submissions. 
    Via Benzinga
    News headline image
    Valneva, Venture Global And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
    Dow futures up 1000 points. Valneva stock falls in pre-market. Pfizer and Valneva announce Phase 3 results for Lyme disease vaccine. Other stocks also down. 
    Via Benzinga
    Topics Stocks
    News headline image
    Pfizer and Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 VALOR Trial
    From Pfizer Inc.
    Via Business Wire
    News headline image
    Have $500? 2 Healthcare Stocks Long-Term Investors Should Buy Right Now ↗
    You can get in on these market giants for bargain prices today. 
    Via The Motley Fool
    Topics Intellectual Property
    News headline image
    2 Unpopular Stocks That Should Get More Attention and 1 We Avoid
    Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad t... 
    Via StockStory
    Topics Supply Chain
    News headline image
    Pfizer Recommends Shareholders Reject the Mini-Tender Offer by Tutanota LLC
    From Pfizer Inc.
    Via Business Wire
    News headline image
    My Top 3 Drug Stocks for March 2026 ↗
    These companies have impressive track records of navigating the biggest challenges in their industry. 
    Via The Motley Fool
    Topics Intellectual Property
    News headline image
    Pfizer vs Moderna: Which Pharma Stock Has More Upside? ↗
    They aren't just "pandemic stocks." 
    Via The Motley Fool
    Topics Intellectual Property
    Which S&P500 stocks are the most active on Thursday? ↗
    Via Chartmill
    News headline image
    Follow the Footprints: 3 Stocks with Unusual Options Activity That You Can’t Ignore
    On a day when nothing worked for investors, yesterday’s unusual options activity had plenty of variety, especially in the top three. Here’s how investors might have played each of the stock's and their... 
    Via Barchart.com
    Topics Economy Stocks
    News headline image
    Is It Too Late to Buy Eli Lilly? ↗
    Eli Lilly's GLP-1 drugs are leaders in a new and exciting drug category, but investors already know this fact. 
    Via The Motley Fool
    Topics Intellectual Property
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    99 100 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.